Another Gloomy Day for Amgen

May 22, 2017 | Bad Credit Loans, Business Lending, Business Loans, Capital, Finance, Non-Bank Loans, Working Capital

Nothing is going right for Amgen these days. It now says its experimental osteoporosis treatment, Evenity, is unlikely to win approval from the Food and Drug Administration this year.